Clinical trial · Interventional
A Study of DCC-2701 in Participants With Advanced Solid Tumors
A Multicenter Phase 1 Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors
NCT02228811CI-TRIAL-00031481terminatedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this study is to investigate the safety of the investigational drug DCC-2701 and whether it will work to help people who have advanced solid tumors or cancer that has spread to other parts of the body.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancers With MET Genomic Alterations | — | UNRESOLVED | — |
| Cancers With TRK Genomic Alterations | — | UNRESOLVED | — |
| Locally Advanced Tumors | Neoplasm | CURATED_BROADER | 0.78 |
| Metastatic Solid Tumors | Solid Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DCC-2701 tablet | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- DCC-2701 tablet
- description
- DCC-2701 tablets in escalating dose cohorts given orally BID (twice daily) every 12 hours for a 28-day cycle. Participants may continue to receive study drug until discontinuation criteria are met.
- interventionNames
- Drug: DCC-2701 tablet
Primary outcomes (1)
- measure
- Maximum Tolerated Dose (MTD) of DCC-2701
- timeFrame
- 28 days (1 cycle)
Secondary outcomes (4)
- measure
- Pharmacokinetics (PK): Maximum Concentration (Cmax) of DCC-2701
- timeFrame
- Cycle 1: Predose and up to 24 hours postdose (Cycle = 28 Days)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Advanced or metastatic solid tumor that has progressed or was not responsive to standard therapy * The cancer has no proven effective therapy * The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required) * Able to swallow tablets Exclusion Criteria: * Have active central nervous system (CNS) metastasis * Have an active infection of any kind (fungal, viral, or bacterial) * Are pregnant or breastfeeding
References
Publications (0)
Data not yet available
No reference posted for this study.